[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100596266":3},{"organization":4,"outcomesModule":7,"designInfo":41,"detailedDescription":47,"studyPopulation":40,"armGroups":48,"interventions":55,"overallOfficials":61,"centralContacts":65,"locations":74,"responsibleParty":93,"collaborators":40,"id":96,"slug":40,"hasResults":97,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":40,"eligibilityCriteria":101,"healthyVolunteers":97,"sex":102,"minAge":103,"maxAge":104,"enrollmentInfo":105,"targetDuration":40,"studyType":108,"phases":109,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":116,"whyStopped":40,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},{"fullName":5,"class":6},"Shanghai Tongji Hospital, Tongji University School of Medicine","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":40},[9,13],{"measure":10,"description":11,"timeFrame":12},"MTD and\u002For dose range","Evaluate Dose limited toxicity and recommended dosage range after CT119X infusion","Up to 28 days after CAR-T cells infusion",{"measure":14,"description":15,"timeFrame":16},"Adverse Events (AE) after CT119X infusion","An assessment of severity grade will be made according to the National Cancer Institute Common Terminology Criteria","12 months after CT119X infusion",[18,22,25,28,31,34,37],{"measure":19,"description":20,"timeFrame":21},"Overall response rate （ORR）","The proportion of patients with complete remission（CR）\u002Fpartial response (PR) after CT119X infusion.","Evaluate at 4, 8, 12 weeks and 6,9,12month after CAR-T infusion",{"measure":23,"description":24,"timeFrame":16},"Complete response rate (CRR)","The proportion of patients with complete response(CR) after CT119X infusion",{"measure":26,"description":27,"timeFrame":16},"Duration of remission(DOR)","Participants achieving CR\u002FPR will be included in the analysis set for DOR. DOR is defined as the time from the date of confirmed response until the date of disease relapse or death from any cause, whichever occurs first.",{"measure":29,"description":30,"timeFrame":16},"Time to response (TTR)","The time from cell infusion to the first assessment of CR or PR",{"measure":32,"description":33,"timeFrame":16},"Time to complete response (TTCR)","The time from cell infusion to the first assessment of CR",{"measure":35,"description":36,"timeFrame":16},"Progression-free survival (PFS)","The time from the infusion of CT119X cells to the first assessment of disease progression or death.",{"measure":38,"description":39,"timeFrame":16},"Overall survival (OS)","defined as the time from the date of receiving the infusion to the date of death from any cause",null,{"allocation":42,"interventionModel":43,"interventionModelDescription":40,"primaryPurpose":44,"observationalModel":40,"timePerspective":40,"maskingInfo":45},"NA","SINGLE_GROUP","TREATMENT",{"masking":46,"maskingDescription":40,"whoMasked":40},"NONE","This is a single-arm, open-label, dose exploratory clinical study to evaluate the safety, efficacy, cellular pharmacokinetics, and pharmacodynamics of CT119X (including CT1190-P and CT1192)cells in patients with B-ALL. It is planned to enroll 6-36participants.",[49],{"label":50,"type":51,"description":52,"interventionNames":53},"CAR-T cells（ chimeric antigen receptor T cells）","EXPERIMENTAL","CT1190B-P and CT1192 cells infusion",[54],"Drug: Chimeric Antigen Receptor T Cells (CAR-T)",[56],{"type":57,"name":58,"description":59,"armGroupLabels":60,"otherNames":40},"DRUG","Chimeric Antigen Receptor T Cells (CAR-T)","chimeric antigen receptor T cells",[50],[62],{"name":63,"affiliation":5,"role":64},"Aibin Liang MD,Ph.D.","PRINCIPAL_INVESTIGATOR",[66,70],{"name":63,"role":67,"phone":68,"phoneExt":40,"email":69},"CONTACT","+86 21 6611 1019","lab7182@tongji.edu.cn",{"name":71,"role":67,"phone":72,"phoneExt":40,"email":73},"Ping Li MD","+86 135 6418 1131","lilyforever@126.com",[75],{"facility":76,"status":40,"city":77,"state":78,"zip":79,"country":80,"countryCode":81,"cosmosGeoPoint":82,"geoPoint":87,"contacts":88},"Shanghai Tongji Hospital","Shanghai","Shanghai Municipality","200065","China","CN",{"type":83,"coordinates":84},"Point",[85,86],121.45806,31.22222,{"lat":86,"lon":85},[89,91,92],{"name":90,"role":67,"phone":68,"phoneExt":40,"email":69},"Aibin Liang MD，Ph.D.",{"name":71,"role":67,"phone":72,"phoneExt":40,"email":73},{"name":63,"role":64,"phone":40,"phoneExt":40,"email":40},{"type":64,"investigatorFullName":94,"investigatorTitle":95,"investigatorAffiliation":5,"oldNameTitle":40,"oldOrganization":40},"Aibin Liang，MD，Ph.D.","Principal Investigator","100596266",false,"NCT07043218","A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed\u002FRefractory B-cell Acute Lymphoblastic Leukemia","A Clinical Study to Investigate the Safety, Efficacy, and Cellular Metabolism of Universal CAR-T Cell in Patients With CD19 and\u002For CD20 Positive Relapsed\u002FRefractory B-cell Acute Lymphoblastic Leukemia.","Inclusion Criteria:\n\n1. Participants must voluntarily sign the informed consent form (ICF) and must be willing and be able to adhere to the study visit schedule and other protocol requirements\n2. 18-75 years old;\n3. Histologically or cytologically confirmed B-ALL;\n4. Previously received at least 2 lines of systemic therapy;\n5. Expected survival \\> 12 weeks;\n6. Eastern Cooperative Oncology Group (ECOG) score 0-2;\n7. Female participants of childbearing potential must have a negative pregnancy test at screening and prior to receiving preconditioning therapy。Both male and Female are willing to use a highly effective and reliable method of contraception for 1 year after receiving study treatment and are absolutely prohibited from donating sperm donation or eggs for 1 year after receiving study treatment infusion during the study.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women;\n2. Has HIV, syphilis infection, active hepatitis B virus infection (HBsAg positive and HBV-DNA above the detection limit), or active hepatitis Cvirus infection (HCV antibody and HCV-DNA positive);\n3. Has any current uncontrolled active infection, including but not limited to participants with active tuberculosis (investigator 's judgment);\n4. Participants' toxicities caused by previous treatment did not recover to Common Terminology Criteria for Adverse Events (CTCAE) ≤ Grade1, except alopecia and other events that are judged tolerable by the investigator;\n5. Patients with isolated extramedullary lesions;\n6. Vaccination with live attenuated vaccines, inactivate vaccines or RNA vaccines within 4 weeks prior to informed consent;\n7. Participants who are allergic or intolerant to preconditioning drugs, tocilizumab, or have other previous history of severe allergy such as anaphylactic shock;\n8. Patients with heart disease in the 6 months prior to screening;\n9. Presence of a second primary malignancy requiring treatment or not in complete remission within the past 2 years;\n10. Serious pulmonary diseases that are judged by the investigator to potentially endanger the patient's life when participating in the study.","ALL","18 Years","75 Years",{"count":106,"type":107},36,"ESTIMATED","INTERVENTIONAL",[110],"PHASE1","A Clinical Study to Investigate the Safety, Efficacy, and Cellular Metabolism of CT119X(including CT1190-P and CT1192) CAR-T Cell therapy, in Patients with Relapsed\u002FRefractory B-cell acute lymphoblastic leukemia.",[113],"B-cell Acute Lymphoblastic Leukemia",[115],"CT119X","NOT_YET_RECRUITING","2025-06-22",{"date":119,"type":120},"2025-06-29","ACTUAL",{"date":122,"type":107},"2025-07-10",{"date":124,"type":107},"2027-06-30",{"name":5,"class":6},1]